TY - JOUR
T1 - The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: A pilot study
AU - Basile, Umberto
AU - Miele, Luca
AU - Napodano, Cecilia
AU - Ciasca, Gabriele
AU - Gulli, F.
AU - Pocino, Krizia
AU - De Matthaeis, Nicoletta
AU - Liguori, Antonio
AU - De Magistris, A.
AU - Marrone, Giuseppe
AU - Biolato, Marco
AU - Marino, Mariapaola
AU - Di Giacinto, Flavio
AU - Gasbarrini, Antonio
AU - Grieco, Antonio
AU - Rapaccini, Gian Ludovico
PY - 2020
Y1 - 2020
N2 - OBJECTIVE: Hepatocellular carcinoma (HCC) is a primary liver tumor derived from metabolic or viral chronic hepatitis, with few treatment options in advanced cases. New biomarkers that allow improving diagnosis and staging are widely desired. Here, we aim to evaluate the performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) in combination with α-fetoprotein (AFP), in the diagnosis of HCC in patients with metabolic or viral hepatitis. PATIENTS AND METHODS: We enrolled 60 HCC patients (20 metabolic and 40 viral) and 20 healthy subjects (HS) as negative controls. PIVKA- II, AFP, Matrix metalloproteinase-9 (MMP-9) and Fibroblast growth factor (FGF) serum levels were assessed by immunoassays. RESULTS: AFP and PIVKA-II levels were obviously higher in patients than in HS. AFP displayed a better diagnostic performance than PIVKA-II for viral HCC while PIVKA-II was better for metabolic HCC. The combination of the two biomarkers did not improve the discriminating ability. CONCLUSIONS: PIVKA-II may be considered an independent predictor of macrovascular invasion from HCC cells and it can be used to better stratify HCC patients and should be evaluated in prospective studies for early detection of advanced HCC in metabolic subjects.
AB - OBJECTIVE: Hepatocellular carcinoma (HCC) is a primary liver tumor derived from metabolic or viral chronic hepatitis, with few treatment options in advanced cases. New biomarkers that allow improving diagnosis and staging are widely desired. Here, we aim to evaluate the performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) in combination with α-fetoprotein (AFP), in the diagnosis of HCC in patients with metabolic or viral hepatitis. PATIENTS AND METHODS: We enrolled 60 HCC patients (20 metabolic and 40 viral) and 20 healthy subjects (HS) as negative controls. PIVKA- II, AFP, Matrix metalloproteinase-9 (MMP-9) and Fibroblast growth factor (FGF) serum levels were assessed by immunoassays. RESULTS: AFP and PIVKA-II levels were obviously higher in patients than in HS. AFP displayed a better diagnostic performance than PIVKA-II for viral HCC while PIVKA-II was better for metabolic HCC. The combination of the two biomarkers did not improve the discriminating ability. CONCLUSIONS: PIVKA-II may be considered an independent predictor of macrovascular invasion from HCC cells and it can be used to better stratify HCC patients and should be evaluated in prospective studies for early detection of advanced HCC in metabolic subjects.
KW - Metabolic Hepatocellular carcinoma
KW - PIVKA-II
KW - Viral Hepatocellular carcinoma
KW - α-fetoprotein
KW - Metabolic Hepatocellular carcinoma
KW - PIVKA-II
KW - Viral Hepatocellular carcinoma
KW - α-fetoprotein
UR - http://hdl.handle.net/10807/170963
U2 - 10.26355/eurrev_202012_24165
DO - 10.26355/eurrev_202012_24165
M3 - Article
SN - 1128-3602
VL - 25
SP - 12675
EP - 12685
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
ER -